Axiom Investors LLC DE Has $2.53 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Axiom Investors LLC DE increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 38.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 69,896 shares of the specialty pharmaceutical company's stock after buying an additional 19,561 shares during the quarter. Axiom Investors LLC DE owned 0.13% of Supernus Pharmaceuticals worth $2,527,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its stake in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth about $52,000. Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals in the fourth quarter valued at about $72,000. Venturi Wealth Management LLC acquired a new position in Supernus Pharmaceuticals in the fourth quarter worth about $92,000. Finally, KBC Group NV lifted its stake in Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock worth $97,000 after purchasing an additional 929 shares during the period.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,104 shares of company stock valued at $440,263. Insiders own 9.30% of the company's stock.

Remove Ads

Supernus Pharmaceuticals Stock Up 0.8 %

SUPN stock traded up $0.25 during midday trading on Friday, reaching $32.74. 1,501,832 shares of the company's stock traded hands, compared to its average volume of 486,335. The company has a 50-day simple moving average of $34.57 and a two-hundred day simple moving average of $35.06. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The company has a market cap of $1.83 billion, a price-to-earnings ratio of 30.60 and a beta of 0.84.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SUPN. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Tuesday. Cantor Fitzgerald reiterated a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.